Continuously strengthen the layout of international business, JENSCARE-B releases interim results with a gross profit of 11.827 million yuan
I'm PortAI, I can summarize articles.
JENSCARE-B released its interim results for the period ending June 30, 2025, with revenue of 13.426 million yuan, gross profit of 11.827 million yuan, and R&D expenses of 88.885 million yuan. The revenue growth is mainly attributed to the commercialization progress of interventional products for treating structural heart diseases. The company has made significant progress in its product pipeline for tricuspid valve, aortic valve, and mitral valve diseases, and continues to increase its international business layout to enhance product influence and clinical application scale
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments